MedTrace Logo

Groningen International Study on Sentinel Nodes in Vulvar Cancer-III

NCT05076942 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 157

Last updated 2023-08-01

No results posted yet for this study

Summary

Vulvar cancer patients with SN-metastasis \> 2mm will receive chemoradiation instead of an inguinofemoral lymphadenectomy.

Conditions

  • Vulvar Cancer
  • Sentinel Lymph Node
  • Lymph Node Metastases

Interventions

RADIATION

Radiotherapy combined with cisplatin

Inguinofemoral radiotherapy combined with weekly cisplatin

DRUG

Cisplatin

Inguinofemoral radiotherapy combined with weekly cisplatin

Sponsors & Collaborators

  • Dutch Cancer Society

    collaborator OTHER

  • NRG Oncology

    collaborator OTHER

  • University Medical Center Groningen

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2028-01-01
Completion
2029-01-01

Countries

  • United States
  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05076942 on ClinicalTrials.gov